Lung cancer trial questions need for immediate brain radiation in asymptomatic patients
NCT ID NCT05236946
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing whether it is safe to delay brain radiotherapy in lung cancer patients with specific genetic mutations (EGFR/ALK) who have asymptomatic brain metastases. Participants will receive standard targeted therapy (TKI) and be randomly assigned to either immediate brain radiation or observation with radiation only if symptoms develop. The study aims to see if delaying radiation can maintain brain tumor control while avoiding unnecessary side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tyrosine kinase inhibitor (TKI) and brain radiotherapy (stereotactic radiosurgery or whole brain radiotherapy)
- What this could lead to
- If successful, this could show that delaying brain radiotherapy is safe for patients with asymptomatic brain metastases, allowing them to avoid side effects while still controlling the disease.
- What could go wrong
- This is a relatively small Phase 3 trial (190 participants) and results may not apply to all lung cancer types. There is a risk that delaying radiotherapy could lead to worse brain tumor control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASYMPTOMATIC BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tata Memorial Hospital
RECRUITINGMumbai, Maharashtra, 400012, India